Predictive value of intrahepatic hepatitis B virus covalently closed circular DNA and total DNA in patients with acute hepatitis B and patients with chronic hepatitis B receiving anti‑viral treatment

Ruan,Peng; Zhou,Boping; Dai,Xiufang; Sun,Zequn; Guo,Xiaoyan; Huang,Jian; Gong,Zuojiong

doi:10.3892/mmr.2014.1972

Predictive value of intrahepatic hepatitis B virus covalently closed circular DNA and total DNA in patients with acute hepatitis B and patients with chronic hepatitis B receiving anti‑viral treatment

Authors:
- Peng Ruan
- Boping Zhou
- Xiufang Dai
- Zequn Sun
- Xiaoyan Guo
- Jian Huang
- Zuojiong Gong
View Affiliations

Affiliations: Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, The Institute of Hepatology, Shenzhen Third People's Hospital, Guangdong Medical College, Shenzhen, Guangdong 518112, P.R. China, Department of Gastroenterology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China
Published online on: February 20, 2014 https://doi.org/10.3892/mmr.2014.1972
Pages: 1135-1141

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study aimed to investigate the persistence and predictive values of intrahepatic (IH) hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) and total DNA (tDNA) in patients with acute hepatitis B (AHB) and patients with chronic hepatitis B (CHB) receiving anti‑viral treatment. The levels of IH cccDNA and tDNA, serum HBV DNA, hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and alanine aminotransferase (ALT) were detected in 11 patients with AHB and 46 patients with CHB who were receiving anti‑viral treatment, among whom 21 had primary treatment failure, 11 achieved virological response (VR) and 15 achieved VR and HBsAg seroclearance. The median IH cccDNA and tDNA levels in the patients with AHB (0.002 copies/cell and 0.04 copies/cell, respectively) were significantly lower than those in the patients with CHB. In the patients with CHB, the median IH cccDNA level among individuals who achieved VR and HBsAg seroclearance (0.012 copies/cell) was significantly lower than that in those who had failed primary treatment (4.18 copies/cell, P<0.0001) but not that in those who achieved solely VR (0.039 copies/cell, P=0.169). The median IH tDNA level in patients with CHB who achevied VR and HBsAg seroclearance (0.096 copies/cell) was significantly lower than that in those who failed primary treatment (371 copies/cell, P<0.0001) and those who achieved solely VR (1.62 copies/cell, P=0.001). No significant difference was observed in the area under the receiver operating characteristic (ROC) curve, which was used to predict the likelihood of achieving VR and HBsAg seroclearance, between IH tDNA and IH cccDNA levels (0.96 and 0.88, respectively; P>0.10). IH cccDNA levels were shown to be positively correlated with serum ALT (P=0.024), HBeAg (P=0.001) and IH tDNA levels (P<0.0001), but not with serum HBV DNA (P=0.12) and HBsAg levels in either HBeAg‑positive (P=0.84) or in HBeAg‑negative (P=0.146) patients. In conclusion, IH cccDNA may persist in patients with AHB and patients with CHB who acheive VR and HBsAg seroclearance following anti‑viral treatment. Furthermore, IH cccDNA and tDNA may have potential in predicting successful therapeutic response in patients with CHB who receive anti‑viral treatment.

View Figures

View References

1	Lok AS and McMahon BJ: Chronic Hepatitis B. Hepatology. 45:507–539. 2007. View Article : Google Scholar
2	Jiang YF, Ma ZH, Zhao PW, Pan Y, Liu YY, Feng JY and Niu JQ: Effect of thymosin-α(1) on T-helper 1 cell and T-helper 2 cell cytokine synthesis in patients with hepatitis B virus e antigen-positive chronic hepatitis B. J Int Med Res. 38:2053–2062. 2010.
3	European association for the study of the liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 50:227–242. 2009. View Article : Google Scholar : PubMed/NCBI
4	Nguyen T, Thompson AJ, Bowden S, et al: Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol. 52:508–513. 2010. View Article : Google Scholar : PubMed/NCBI
5	Wong DK, Huang FY, Lai CL, et al: Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology. 54:829–836. 2011. View Article : Google Scholar : PubMed/NCBI
6	Lau GK, Liang R, Chiu EK, Lee CK and Lam SK: Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant. 19:795–799. 1997. View Article : Google Scholar : PubMed/NCBI
7	Chaiteerakij R, Komolmit P, Sa-nguanmoo P and Poovorawan Y: Intrahepatic HBV DNA and covalently closed circular DNA (cccDNA) levels in patients positive for anti-HBc and negative for HBsAg. Southeast Asian J Trop Med Public Health. 41:867–875. 2010.PubMed/NCBI
8	Sung JJ, Wong ML, Bowden S, et al: Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology. 128:1890–1897. 2005. View Article : Google Scholar : PubMed/NCBI
9	Bowden S, Jackson K, Littlejohn M and Locarnini S: Quantification of HBV covalently closed circular DNA from liver tissue by real-time PCR. Methods Mol Med. 95:41–50. 2004.PubMed/NCBI
10	Weinberger KM, Wiedenmann E, Böhm S and Jilg W: Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system (TaqMan PCR). J Virol Methods. 85:75–82. 2000. View Article : Google Scholar : PubMed/NCBI
11	Ramezani A, Banifazl M, Mamishi S, Sofian M, Eslamifar A and Aghakhani A: The influence of human leukocyte antigen and IL-10 gene polymorphisms on hepatitis B virus outcome. Hepat Mon. 12:320–325. 2012. View Article : Google Scholar : PubMed/NCBI
12	Chang JJ and Lewin SR: Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol. 85:16–23. 2007. View Article : Google Scholar : PubMed/NCBI
13	Sun C, Fu B, Gao Y, Liao X, Sun R, Tian Z and Wei H: TGF-β1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence. PLoS Pathog. 8:e10025942012.
14	Chinese Society of Hepatology and Chinese Society of Infectious Diseases; Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Gan Zang Bing Za Zhi. 19:13–24. 2011.(In Chinese).
15	Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G and Dandri M: Control of cccDNA function in hepatitis B virus infection. J Hepatol. 51:581–592. 2009. View Article : Google Scholar : PubMed/NCBI
16	Wang M, Qiu N, Lu S, et al: Serum hepatitis B surface antigen is correlated with intrahepatic total HBV DNA and cccDNA in treatment-naïve patients with chronic hepatitis B but not in patients with HBV related hepatocellular carcinoma. J Med Virol. 85:219–227. 2013.PubMed/NCBI
17	Manesis EK, Papatheodoridis GV, Tiniakos DG, et al: Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol. 55:61–68. 2011. View Article : Google Scholar : PubMed/NCBI
18	Pollicino T, Belloni L, Raffa G, Pediconi N, Squadrito G, Raimondo G and Levrero M: Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology. 130:823–837. 2006. View Article : Google Scholar : PubMed/NCBI
19	Vivekanandan P, Thomas D and Torbenson M: Methylation regulates hepatitis B viral protein expression. J Infect Dis. 199:1286–1291. 2009. View Article : Google Scholar : PubMed/NCBI
20	Belloni L, Allweiss L, Guerrieri F, et al: IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. 122:529–537. 2012.
21	Volz T, Lutgehetmann M, Wachtler P, et al: Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology. 133:843–852. 2007. View Article : Google Scholar : PubMed/NCBI
22	Werle-Lapostolle B, Bowden S, Locarnini S, et al: Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 126:1750–1758. 2004. View Article : Google Scholar
23	Chou YC, Jeng KS, Chen ML, et al: Evaluation of transcriptional efficiency of hepatitis B virus covalently closed circular DNA by reverse transcription-PCR combined with the restriction enzyme digestion method. J Virol. 79:1813–1823. 2005. View Article : Google Scholar
24	Xu WS, Zhao KK, Miao XH, Ni W, Cai X, Zhang RQ and Wang JX: Effect of oxymatrine on the replication cycle of hepatitis B virus in vitro. World J Gastroenterol. 16:2028–2037. 2010. View Article : Google Scholar : PubMed/NCBI
25	Jiang Z, Jhunjhunwala S, Liu J, et al: The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res. 22:593–601. 2012. View Article : Google Scholar : PubMed/NCBI
26	Thompson AJ, Nguyen T, Iser D, et al: Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology. 51:1933–1944. 2010. View Article : Google Scholar
27	Jaroszewicz J, Calle Serrano B, Wursthorn K, et al: Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective. J Hepatol. 52:514–522. 2010. View Article : Google Scholar : PubMed/NCBI
28	Chan HL, Wong VW, Tse AM, et al: Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol. 5:1462–1468. 2007. View Article : Google Scholar : PubMed/NCBI
29	Takkenberg RB, Zaaijer HL, Menting S, et al: Detection of hepatitis B virus covalently closed circular DNA in paraffin-embedded and cryo-preserved liver biopsies of chronic hepatitis B patients. Eur J Gastroenterol Hepatol. 22:952–960. 2010. View Article : Google Scholar : PubMed/NCBI
30	Zhou T, Guo H, Guo JT, Cuconati A, Mehta A and Block TM: Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays. Antiviral Res. 72:116–124. 2006. View Article : Google Scholar : PubMed/NCBI
31	Moucari R, Mackiewicz V, Lada O, et al: Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology. 49:1151–1157. 2009. View Article : Google Scholar : PubMed/NCBI